Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis

F. Palandri, R. Latagliata, N. Polverelli, A. Tieghi, M. Crugnola, B. Martino, M. Perricone, M. Breccia, E. Ottaviani, N. Testoni, F. Merli, F. Aversa, G. Alimena, M. Cavo, G. Martinelli, L. Catani, M. Baccarani, N. Vianelli

Research output: Contribution to journalArticle

Abstract

We investigated the influence of molecular status on disease characteristics and clinical outcome in young patients (≤40 years) with World Health Organization (WHO)-defined essential thrombocythemia (ET) or early/prefibrotic primary myelofibrosis (early-PMF). Overall, 217 patients with ET (number 197) and early-PMF (number 20) were included in the analysis. Median follow-up time was 10.2 years. The cumulative incidence of thrombosis, hemorrhages and disease evolution into myelofibrosis/acute leukemia were 16.6%, 8.6% and 3% at 15 years, respectively. No differences were detectable between ET and early-PMF patients, although the latter cohort showed a trend for worse combined-event free survival (EFS). Mutation frequency were 61% for JAK2V617F, 25% for CALR and 1% for MPLW515K, and were comparable across WHO diagnosis; however, JAK2V617F allele burden was higher in the early-PMF group. Compared with JAK2V617F-positive patients, CALR-mutated patients displayed higher platelet count and lower hemoglobin level. CALR mutations significantly correlated with lower thrombotic risk (9.1% versus 21.7%, P=0.04), longer survival (100% versus 96%, P=0.05) and better combined-EFS (86% versus 71%, P=0.02). However, non-type 1/type 2 CALR mutations ('minor' mutations) and abnormal karyotype were found to correlate with increased risk of disease evolution. At last contact, six patients had died; in five cases, the causes of death were related to the hematological disease and occurred at a median age of 64 years (range: 53-68 years). Twenty-eight patients (13%) were unmutated for JAK2, CALR and MPL: no event was registered in these 'triple-negative' patients.

Original languageEnglish
Pages (from-to)1344-1349
Number of pages6
JournalLeukemia
Volume29
Issue number6
DOIs
Publication statusPublished - Jun 9 2015

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine
  • Medicine(all)

Fingerprint Dive into the research topics of 'Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis'. Together they form a unique fingerprint.

  • Cite this

    Palandri, F., Latagliata, R., Polverelli, N., Tieghi, A., Crugnola, M., Martino, B., Perricone, M., Breccia, M., Ottaviani, E., Testoni, N., Merli, F., Aversa, F., Alimena, G., Cavo, M., Martinelli, G., Catani, L., Baccarani, M., & Vianelli, N. (2015). Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. Leukemia, 29(6), 1344-1349. https://doi.org/10.1038/leu.2015.87